Reading this on a mobile device? Try our optimized mobile version here:

December 11, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
  • Initiatives aim to reduce bleeding and other birth complications
    The CDC is funding initiatives across the U.S. to help build guidelines and protocols that improve safety during childbirth and prevent complications including severe bleeding and blood clots. The programs include drills that involve blood loss simulations and massive transfusion protocols to train doctors and nurses in quickly responding to maternal complications. Childbirth emergencies increased by 75% in the 10 years ending in 2009, according to a new report from the CDC. The Wall Street Journal (12/10) LinkedInFacebookTwitterEmail this Story
NEW Complement Coated C3 Control Cells!
Hemo bioscience has received FDA clearance for its complement coated control cells. Hemo bioscience C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin tests. For details regarding pricing, manufacturing schedule, and distribution channels email us or call 866-332-2835.

  Science & Health 
  • Quizartinib is beneficial for patients with AML, study says
    More than one-third of patients with acute myeloid leukemia experienced complete remission following treatment with the new drug quizartinib, or AC220, allowing many to receive bone marrow transplants, according to findings from a midstage trial. The study involved 137 patients, most with the leukemia cell genetic variation FLT3-ITD. Tests are continuing at lower doses. Yahoo/Asian News International (12/10) LinkedInFacebookTwitterEmail this Story
  • Deferasirox reduces iron levels in children with thalassemia
    The anti-iron overload drug deferasirox appeared safe for pediatric patients with thalassemia who were treated for up to three years, according to an Egyptian study. Treatment also was linked to reductions in serum iron levels, researchers said. "We know that deferasirox works well in adults. Now we see that it works just as well in children," said researcher Dr. Amal El-Beshlawy of Cairo University. MedPage Today (free registration) (12/10) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • Strong growth of ACOs expected in 2013
    Experts predict a rapid increase in the number of accountable care organizations in 2013. "This is becoming a more pervasive phenomenon," said Dr. Norman Chenven of the Austin Regional Clinic. As many as 31 million patients are involved in some way with the ACO model, according to consulting company Oliver Wyman. American Medical News (free content) (12/10) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 

Distance Education Masters at George Washington University
For those enrolled in an SBB program or SBB certified. Twenty-two hours of distance education courses in areas such as molecular biology, current topics in transfusion medicine, immunology and a research project in an area of immunohematology. Learn More.

  Government & Regulatory 
  • FDA's approval sought to use genetically engineered mosquitoes
    Officials in Florida are asking for the FDA's OK to release biotech mosquitoes from the British company Oxitec to control a breed of mosquito that spreads dengue fever. Oxitec conducted a field test of mosquitoes designed to produce nonviable offspring in 2010 on Grand Cayman Island. No timetable is set for a decision, according to an FDA spokeswoman. ABC News/"World News" (12/8) LinkedInFacebookTwitterEmail this Story
  • Data on compounding group's role sought by House panel
    The House Energy and Commerce Committee requested information from the International Academy of Compounding Pharmacists on its role in helping pharmacies interact with federal and state regulators. The move came as the committee continues to probe a meningitis outbreak tied to tainted compounded treatments. Ten lawmakers cited a media report that the group told pharmacists how to "sidestep" FDA requests for samples. Reuters (12/7) LinkedInFacebookTwitterEmail this Story
  Association News 
  • AABB requests nominations for 2013, 2014 memorial awards
    AABB is seeking nominations for its 2013 and 2014 memorial awards, which will honor individuals who have advanced the practice of transfusion medicine and cellular therapies. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form by Jan. 25. Recipients will be honored at the 2013 AABB Annual Meeting in Denver or the 2014 AABB Annual Meeting in Philadelphia. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

Put a grain of boldness into everything you do."
--Baltasar Gracián,
Spanish writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information